Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Hematologic Malignancies
NCT ID: NCT03727009
Last Updated: 2021-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
409 participants
OBSERVATIONAL
2018-12-07
2020-03-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Melanoma
NCT03727087
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
NCT03662204
Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
NCT03628651
Collection of Biological Specimens and Associated Health Information
NCT06369441
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
NCT05181826
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hematologic Malignancy
Subjects with clinically confirmed hematologic malignancy and who are treatment naive will provide a blood sample at the time of enrollment. No additional blood draws will occur.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood Sample Collection
Subjects participating in the study will have blood drawn at enrollment.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has an untreated hematologic malignancy.
* Subject understands the study procedures and is able to provide informed consent to participate in the study and authorization for release of relevant protected health information to the study Investigator.
Exclusion Criteria
* Chemotherapy and/or radiation therapy within 5 years prior to enrollment/sample collection.
* Any treatment for the primary malignancy. Subject may not have started neo-adjuvant chemotherapy, neo-adjuvant radiation therapy, immunotherapy or other treatment prior to blood sample collection.
* Less than 3 days between fine needle aspiration (FNA) of target pathology and blood collection.
* Less than 7 days between biopsy (other than FNA) of target pathology and blood collection.
* IV contrast (e.g. CT and MRI) within 1 day \[or 24 hours\] of blood collection.
* Individual has a condition the Investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Exact Sciences Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Fort Smith
Fort Smith, Arkansas, United States
CARTI Cancer Center
Little Rock, Arkansas, United States
Marin Cancer Care
Greenbrae, California, United States
Alliance Research Centers
Laguna Hills, California, United States
North County Oncology
Oceanside, California, United States
Middlesex Hospital
Middletown, Connecticut, United States
The Stamford Hospital
Stamford, Connecticut, United States
Mid-Florida Hematology and Oncology Center
Orange City, Florida, United States
PMG Research, INC
Downers Grove, Illinois, United States
Illinois CancerCare-Peoria
Peoria, Illinois, United States
Orchard Healthcare Research, Inc.
Skokie, Illinois, United States
Carle Cancer Center NCI
Urbana, Illinois, United States
Indiana Blood and Marrow Transportation
Indianapolis, Indiana, United States
St. Elizabeth Medical Center
Edgewood, Kentucky, United States
Baptist Health Lexington
Lexington, Kentucky, United States
Baptist Health Louisville
Louisville, Kentucky, United States
Baptist Health Paducah
Paducah, Kentucky, United States
RCCA MD Inc.
Bethesda, Maryland, United States
Cancer Research Consortium of West Michigan
Grand Rapids, Michigan, United States
HealthPartner Institute
Bloomington, Minnesota, United States
Mercy Joplin
Joplin, Missouri, United States
Mercy Springfield
Springfield, Missouri, United States
Mercy St. Louis
St Louis, Missouri, United States
East Carolina University Brody School of Medicine
Greenville, North Carolina, United States
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina, United States
Mercy Oklahoma City
Oklahoma City, Oklahoma, United States
Bon Secours St Francis Cancer Center
Greenville, South Carolina, United States
Spartanburg Regional Healthcare District
Spartanburg, South Carolina, United States
Lexington Medical Center
West Columbia, South Carolina, United States
Rapid City Regional Hospital
Rapid City, South Dakota, United States
Community Cancer Trials of Utah
Ogden, Utah, United States
Wenatchee Valley Hospital
Wenatchee, Washington, United States
CAMC Clinical Trials Center
Charleston, West Virginia, United States
Dean Clinic - Fort Atkinson Specialty Services
Fort Atkinson, Wisconsin, United States
ProHealth Care
Oconomowoc, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-02
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.